Review of rituximab in primary CNS lymphoma

Pawan K. Singh; Edward Pan

doi:10.1016/j.jns.2019.116649

Review of rituximab in primary CNS lymphoma

Pawan K. Singh, Edward Pan

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Primary CNS lymphoma (PCNSL) is a rare intracranial tumor. Several treatment regimens exist, but there is no one established standard of care regimen. This article reviews the effects of the addition of rituximab to induction chemotherapy for PCNSL patients. The addition of rituximab in phase II trials seems to increase the overall response rates (ORR) of PCNSL patients, especially when they receive consolidation therapy after rituximab-based induction chemotherapy regimens. Upfront rituximab added to MBVP chemotherapy did not improve overall survival in PCNSL patients, but it may benefit specific subpopulations of PCNSL patients. This review highlights the potential benefit of rituximab as part of induction chemotherapy with consolidation treatment.

Original language	English (US)
Article number	116649
Journal	Journal of the Neurological Sciences
Volume	410
DOIs	https://doi.org/10.1016/j.jns.2019.116649
State	Published - Mar 15 2020

Keywords

Clinical trials
Methotrexate
Primary CNS lymphoma
Rituximab

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1016/j.jns.2019.116649

Cite this

@article{77e74c04ac894c768c0d0a8ffad0c9b8,

title = "Review of rituximab in primary CNS lymphoma",

abstract = "Primary CNS lymphoma (PCNSL) is a rare intracranial tumor. Several treatment regimens exist, but there is no one established standard of care regimen. This article reviews the effects of the addition of rituximab to induction chemotherapy for PCNSL patients. The addition of rituximab in phase II trials seems to increase the overall response rates (ORR) of PCNSL patients, especially when they receive consolidation therapy after rituximab-based induction chemotherapy regimens. Upfront rituximab added to MBVP chemotherapy did not improve overall survival in PCNSL patients, but it may benefit specific subpopulations of PCNSL patients. This review highlights the potential benefit of rituximab as part of induction chemotherapy with consolidation treatment.",

keywords = "Clinical trials, Methotrexate, Primary CNS lymphoma, Rituximab",

author = "Singh, {Pawan K.} and Edward Pan",

note = "Publisher Copyright: {\textcopyright} 2019 Elsevier B.V.",

year = "2020",

month = mar,

day = "15",

doi = "10.1016/j.jns.2019.116649",

language = "English (US)",

volume = "410",

journal = "Journal of the Neurological Sciences",

issn = "0022-510X",

publisher = "Elsevier",

}

TY - JOUR

T1 - Review of rituximab in primary CNS lymphoma

AU - Singh, Pawan K.

AU - Pan, Edward

PY - 2020/3/15

Y1 - 2020/3/15

N2 - Primary CNS lymphoma (PCNSL) is a rare intracranial tumor. Several treatment regimens exist, but there is no one established standard of care regimen. This article reviews the effects of the addition of rituximab to induction chemotherapy for PCNSL patients. The addition of rituximab in phase II trials seems to increase the overall response rates (ORR) of PCNSL patients, especially when they receive consolidation therapy after rituximab-based induction chemotherapy regimens. Upfront rituximab added to MBVP chemotherapy did not improve overall survival in PCNSL patients, but it may benefit specific subpopulations of PCNSL patients. This review highlights the potential benefit of rituximab as part of induction chemotherapy with consolidation treatment.

AB - Primary CNS lymphoma (PCNSL) is a rare intracranial tumor. Several treatment regimens exist, but there is no one established standard of care regimen. This article reviews the effects of the addition of rituximab to induction chemotherapy for PCNSL patients. The addition of rituximab in phase II trials seems to increase the overall response rates (ORR) of PCNSL patients, especially when they receive consolidation therapy after rituximab-based induction chemotherapy regimens. Upfront rituximab added to MBVP chemotherapy did not improve overall survival in PCNSL patients, but it may benefit specific subpopulations of PCNSL patients. This review highlights the potential benefit of rituximab as part of induction chemotherapy with consolidation treatment.

KW - Clinical trials

KW - Methotrexate

KW - Primary CNS lymphoma

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=85077030128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077030128&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2019.116649

DO - 10.1016/j.jns.2019.116649

M3 - Article

C2 - 31901591

AN - SCOPUS:85077030128

SN - 0022-510X

VL - 410

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

M1 - 116649

ER -

Review of rituximab in primary CNS lymphoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this